Why access to biologic medicines matters
Demand for biologic medicines continues to grow. At the same time, patients and healthcare systems in many parts of the world still face challenges in accessing these treatments.
Biosimilars are highly similar to an already approved reference biologic medicine and must meet applicable regulatory standards for quality, safety and efficacy. By increasing competition and treatment options, biosimilars can contribute to broader access and may help reduce costs for healthcare systems.
How Fresenius Kabi works to broaden access worldwide
As part of Fresenius, Fresenius Kabi’s Biopharma business is committed to making life-changing biologic medicines accessible to more patients worldwide. We combine scientific expertise, integrated development and manufacturing capabilities, and global supply reach. Building on Fresenius Kabi’s broader infrastructure spanning more than 100 countries, we work to make high-quality biologic medicines more accessible and affordable.
By developing, manufacturing and supplying biosimilars, we aim to help close treatment access and cost gaps to contribute to the long-term sustainability of healthcare systems worldwide.
What it takes to realize the value of biosimilars
Realizing the full value of biosimilars requires more than regulatory approval. Expanding access depends on confidence in the science, reliable supply, informed treatment decisions and healthcare policies that support access and adoption. Collaboration across healthcare professionals, patient communities, policymakers, partners and industry can help address barriers and enable more patients to benefit from biologic medicines.
Global Biosimilars Week 2026 is an opportunity to focus on these practical conditions for access and on how biosimilars can contribute to resilient, sustainable healthcare systems worldwide.
